HC Wainwright Forecasts FibroBiologics FY2030 Earnings

FibroBiologics Inc. (NASDAQ:FBLG) – Investment analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of FibroBiologics in a report issued on Thursday, February 26th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.62) per share for the year. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share.

FibroBiologics (NASDAQ:FBLG) last released its earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.06.

Other equities analysts have also issued research reports about the stock. D. Boral Capital decreased their price target on shares of FibroBiologics from $15.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, FibroBiologics presently has an average rating of “Hold” and an average target price of $5.50.

FibroBiologics Stock Performance

FibroBiologics stock opened at $0.33 on Friday. The stock’s 50 day moving average price is $0.29 and its two-hundred day moving average price is $0.39. The stock has a market capitalization of $22.21 million, a price-to-earnings ratio of -0.78 and a beta of -0.60. FibroBiologics has a 52-week low of $0.22 and a 52-week high of $1.53.

Institutional Trading of FibroBiologics

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new position in shares of FibroBiologics during the first quarter valued at about $29,000. XTX Topco Ltd boosted its holdings in FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after acquiring an additional 28,276 shares during the period. Ethos Financial Group LLC grew its position in FibroBiologics by 100.0% during the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after acquiring an additional 24,424 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in FibroBiologics in the 2nd quarter worth approximately $37,000. Finally, Marshall Wace LLP bought a new stake in FibroBiologics in the second quarter valued at approximately $49,000.

Insider Activity at FibroBiologics

In other FibroBiologics news, General Counsel Ruben A. Garcia bought 140,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the transaction, the general counsel directly owned 140,000 shares in the company, valued at $47,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 13.00% of the company’s stock.

Key Stories Impacting FibroBiologics

Here are the key news stories impacting FibroBiologics this week:

• Positive Sentiment: HC Wainwright sharply raised EPS forecasts across 2026–2030 (quarterly upgrades to about ($0.07)–($0.08) in 2026 and materially improved FY2026–FY2029 projections) and reiterated a “Buy” rating with a $4.00 target — analysts now model a smaller loss trajectory than before, which supports higher valuation expectations. HC Wainwright estimate upgrades (MarketBeat)
• Positive Sentiment: Company messaging: FibroBiologics says it is “ready to transition to a clinical-stage company,” a strategic milestone that can increase investor interest and provide near‑term clinical and regulatory catalysts. FBLG: Ready to Transition to Clinical-Stage Company
• Neutral Sentiment: FibroBiologics released full-year 2025 financial results and a corporate update; investors should read the release for details on cash runway, R&D spend and guidance that will determine how quickly the company can advance programs. Full Year 2025 Financial Results and Corporate Update
• Neutral Sentiment: Short-interest reporting is effectively zero in the available data (no meaningful days-to-cover), so short squeezes are unlikely to be a driver in the near term; liquidity and volume remain relevant for price moves. (Internal short-interest update)
• Negative Sentiment: D. Boral Capital reduced its price target on FBLG to $7.00 — a downward revision from its prior view — which introduces a cautionary analyst perspective even though the revised target remains above some other published objectives. D. Boral Capital Cuts FibroBiologics Price Target to $7.00

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.